Natco Pharma

Natco Pharma
Company typePublic
NSE: NATCOPHARM
BSE: 524816
IndustryPharmaceuticals
Founded1981
FounderVC Nannapaneni
Headquarters
Hyderabad, Telangana
,
India
Area served
Global
Key people
VC Nannapaneni (Chairman and MD)[1]
Rajeev Nannapaneni (CEO and Vice Chairman)[2]
Revenue ₹4,784 crore (US$570 million) (2025)
₹2,550 crore (US$300 million) (2025)
₹1,883 crore (US$220 million) (2025)
Websitenatcopharma.co.in
Footnotes / references
Financials as of 31 March 2025.[3]

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products.[4] It is a major producer of branded oncology medicines[5] cardiology, diabetology and other pharma specialty drugs[6] at affordable prices.[7][8][9][10]

History

  • In 1981: Venkaiah Choudary Nannapaneni founded NATCO Pharma with the objective of "making specialty medicines accessible to all."
  • In 1981: Kothur unit began with the production of formulations.
  • In 1986: Operations commenced by manufacturing parental at the facility in Nagarjuna Sagar.
  • In 1992: NATCO Pharma went public on 1st July 1992.
  • In 1993: Chemical division at Mekaguda, Telangana commenced with the production of APIs and intermediates.
  • In 2003: The oncology division was launched with the flagship brand VEENAT (generic Imatinib Mesylate) for treating Chronic myelogenous leukemia.
  • In 2008: Natco Pharma filed its first paragraph IV filing in the US with the USFDA.[11]
  • In 2009: The company established an organics facility for Cytotoxic APIs and biotechnology products in Chennai.
  • In 2011: Established its subsidiary NATCO Pharma do Brazil LTDA in Brazil.
  • In 2012: Natco Pharma obtained a compulsory license to produce a cheaper and generic version of Bayer's anti‑cancer medication Nexavar.[6]
  • In 2013: Natco Pharma Canada Inc. was established to facilitate sales and distribution in Canada.
  • In 2016: The generic version of Oseltamivir Phosphate capsules was launched in the United States.
  • In 2017: Started the Cardiology and Diabetology division with the launch of Dabigatran in India.
  • In 2017: Launched Glatiramer Acetate injection and complex drug product Liposomal Doxorubicin in the United States.
  • In 2019: NATCO Crop Health Sciences division was launched.
  • In 2022: First generic version of Revlimid in the United States market.
  • In 2022: Crop Health Sciences launched Chlorantraniliprole (CTPR) agro products in India.
  • In 2022: Invested in a cell therapy company that developed a patented experimental treatment for dry AMD called Eyecyte-RPE.
  • In 2023: NATCO set up its subsidiaries in Indonesia and Colombia to boost international business.
  • In 2024: Highest-ever revenue of Rs 41,169 million, EBIDTA of Rs 18,795 million, and PAT of Rs 13,883 million.
  • In 2024: Invested INR 15 Cr in Cellogen Therapeutics Pvt Ltd., focusing on cell and gene therapy solutions.
  • In 2024: Invested in eGenesis, a biotechnology company focused on xenotransplantation.
  • In 2025: On 11 November, Natco Pharma completed the acquisition of a 35.75% stake in Adcock Ingram Holdings Limited, a South African pharmaceutical company founded in 1891 that manufactures prescription, over-the-counter, consumer, and hospital pharmaceutical products and is known for brands such as Panado, Myprodol, Epi-Max, Citro-Soda, and Allergex. The transaction, valued at approximately US$226 million, resulted in the delisting of Adcock Ingram from the Johannesburg Stock Exchange. Following the acquisition, the combined entity reported revenue exceeding US$1 billion with total assets of approximately US$1.5 billion.[12][13][14]

References

  1. ^ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
  2. ^ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
  3. ^ "Earnings Presentation - Q4 FY25 & FY25" (PDF). NATCO Pharma Limited. Retrieved 11 July 2025.
  4. ^ "Our Business | Natco Pharma". Retrieved 25 April 2022.
  5. ^ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
  6. ^ a b "How Natco Defied the Odds to Rise up India's Pharma Ladder". Moneycontrol. 19 April 2020. Retrieved 11 March 2026. "How Natco Defied the Odds to Rise up India's Pharma Ladder". Moneycontrol. 19 April 2020. Retrieved 11 March 2026. Cite error: The named reference "Ladder" was defined multiple times with different content (see the help page).
  7. ^ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
  8. ^ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
  9. ^ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
  10. ^ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
  11. ^ "Natco Pharma's First Paragraph IV Filing in US". Business Standard. 27 February 2008. Retrieved 11 March 2026.
  12. ^ "Natco completes 35.75% stake buy in South African firm". Moneycontrol. 12 November 2025. Retrieved 11 March 2026.
  13. ^ "Natco Pharma completes Adcock Ingram delisting from JSE". HDFC Sky. 12 November 2025. Retrieved 11 March 2026.
  14. ^ "Natco Pharma to acquire significant stake in South African firm Adcock Ingram". Economic Times Pharma. 2025. Retrieved 11 March 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.